Bronckers IMGJ, Paller AS, West DP, et al. - A retrospective medical records review was conducted at 20 European and North American centers to evaluate the real-world, 6-month reduction in psoriasis severity and long-term drug survival (rate and duration of adherence to a specific drug) of methotrexate vs biologics in plaque psoriasis in children. A total of 234 pediatric individuals (103 boys [44.0%]; 131 girls [56.0%]) were included in this study. The results of this study demonstrated that in pediatric psoriasis, methotrexate and biologics seem to be correlated with improvement, although biologics appear to be correlated with a greater decline in psoriasis severity scores and higher drug survival rates than methotrexate in the real-world setting. Further investigations directly comparing these medications should be conducted for confirmation.